Clinical trial
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small…
NCT00389805 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00389805 |
|---|---|
| Title | Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors |
| Official title | Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Genetic, Other |
| Interventions | bortezomib, pemetrexed disodium, gene expression analysis, mutation analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method |
| Enrollment | 27 |
| Start date | Mar 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Oct 19, 2006 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: